Aspirin, caffeine (Anadin, Extra Strength Anadin)
Aspirin, caffeine
Haleon South Africa (Pty) Ltd
Registration
- Applicant
- Haleon South Africa (Pty) Ltd
- Certificate holder
- Glaxosmithkline Consumer Healthcare South Africa (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Anadin tablets EACH TABLET CONTAINS: ASPIRIN 400 mg, CAFFEINE 22,7 mg | 400.0 mgUncoated tablet | B0835B/2.8/835Approved 6 May 2021 | Registered | Not determined | PIPIL |
| Extra strength anadin EACH TABLET CONTAINS: ASPIRIN 500 mg ,CAFFEINE 32 mg | Not listed | N0176N/2.8/176 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Caffeine
- when intended for injection.
Consolidated Schedules 06 July 2026, line 3256
S2: Aspirin
- the treatment of children or adolescents; and
- the prophylaxis of cardiovascular disease in adults (S0)
Consolidated Schedules 06 July 2026, lines 1616 to 1620
1 of 10 approved products with this ingredient carry S5 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.